N@N

Rosetta Genomics Ltd (NASDAQ:ROSG), Up By 6.84% ($0.32) From $4.680 After BUYINS.NET Report Predicted Stock Would Go Up Due To

November 8, 2012 / M2 PRESSWIRE / BUYINS.NET, www.buyins.net , a provider of unique trading technologies, released a report on Wednesday, November 7th 2012 stating that Rosetta Genomics Ltd (NASDAQ:ROSG) was expected to go Up due to the Bullish conditions presented in the following report. Click here to view the BUYINS.NET report: http://www.buyins.net/releases/?sym=rosg&id=325760

At the time this story was written, Rosetta Genomics Ltd (NASDAQ:ROSG) is Up By $0.32 (6.84%) since the BUYINS.NET report was released.

The movement of stock prices in the days and weeks leading to and following specific fundamental or technical events may follow a predictable pattern. Many companies stock price histories show random or unpredictable movements around certain events. But some seem to repeat the same pattern quarter after quarter, year after year. We use powerful computers to uncover those events and correlations to generate predictions with high probabilities of generating very specific returns within very specific time periods.

The specific technology used to make these predictions is available for a low monthly fee at http://www.squeezetrigger.com/services/strat/mh.php

Rosetta Genomics Ltd (NASDAQ:ROSG) - Rosetta Genomics Ltd. develops microRNA-based diagnostic and in Israel. MicroRNAs are naturally expressed, or produced, using instructions encoded in deoxyribonucleic acid and are used in regulating protein production. The company develops microRNA-based diagnostic programs for various cancers, as well as for the identification of the origin of the primary tumor of metastases; for differentiating squamous from non squamous non-small cell lung cancer; and for differentiating mesothelioma from other carcinomas in the lung and pleura. The company also focuses on the development of body fluid-based diagnostic tests. In addition, it develops microRNA-based therapeutic products for the treatment of liver cancer. The company has a license and collaboration agreement with Prometheus Laboratories Inc. to license and sublicense certain rights related to the companys microRNA-based cancer diagnostic tests; and a collaboration agreement with CBR Institute for Biomedical Research to study the role of microRNAs in hematopoeisis. Rosetta Genomics Ltd. was founded in 2000 and is based in Rehovot, Israel.. There is a failure to deliver in shares of ROSG

About BUYINS.NET

BUYINS.NET, www.buyins.net , monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market-maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:

REGULATORY & COMPLIANCE NEWS

Friction Factor market-maker surveillance system tracking Level II market-makers in all stocks to determine Price Friction and compliance with new "Fair Market-Making Requirements"

RegSHO Naked Shorts -- tracks EVERY failure to deliver in all US stocks and tracks all Threshold Security Lists daily for which stocks have naked shorts that are not in compliance with Regulation SHO

INVESTMENTS & TRADING

SqueezeTrigger -- 30 billion cell database tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock.

Earnings Edge -- predicts probability, price move and length of move before and after all US stock earnings reports.

Seasonality -- predicts probability, price move and length of move based on exact time of year for all US stocks.

Group Trader -- tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups.

Pattern Scan -- automates tracking of every technical pattern and predicts time and size of move in all stocks.

GATS (Global Automated Trading System) -- tracks all known trading strategies and qualifies and quantifies which are working best in real time.

DISCLAIMER:

BUYINS.NET is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. BUYINS.NET has not been compensated by any of the above mentioned companies specifically for this report, but may have been compensated up to $1,200 per month in the past for unrelated data or report services. Past performance is not indicative of future results. Please visit our web site, www.buyins.net , for complete risks and disclosures.

Contact: BUYINS.NET Thomas Ronk 800-715-9999 tom@buyins.net http://www.buyins.net

Contributing Sources

---